Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol

Next Previous
Trial Profile

A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allopurinol (Primary) ; Lesinurad (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms CLEAR Extension
  • Sponsors Ardea Biosciences

Most Recent Events

  • 17 Jun 2017 Pooled safety results from three large pivotal studies and their extensions (CRYSTAL, CLEAR-1, CLEAR-2, CRYSTAL extension and CLEAR extension), presented at the 18th Annual Congress of the European League Against Rheumatism
  • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
  • 13 Nov 2016 Integrated safety data for lesinurad based on patients from CLEAR 1, CLEAR 2, CRYSTAL, CLEAR extension and CRYSTAL extension trials were presented at the American College of Rheumatology 2016 Annual Meeting, according to an Ironwood Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top